Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Hydroxybenzotriazole Monohydrate, often written as HOBT, came into the picture in the mid-20th century when scientists searched for safer and more effective ways to drive peptide bond formation. Before HOBT, synthetic organic chemists had a tough time with side reactions and low yields. By adding HOBT into peptide coupling, peptide research took a leap forward. It reduced dangerous byproducts and made the process cleaner, and it wasn’t long until pharmaceutical labs and peptide chemists adopted it as a standard coupling additive. Over the decades, HOBT saw expanded use right along with the rise of peptide-based drugs, especially as more developed countries poured resources into biopharma and generic drug scale-up. Many of today’s medicines trace their roots to scientists who relied heavily on HOBT to turn earlier peptide procedures into useful products.
Hydroxybenzotriazole Monohydrate is sold as a white crystalline powder that dissolves easily in water and certain polar organic solvents. It works mainly as an additive rather than a stand-alone reagent. HOBT holds particular value in peptide synthesis by mitigating racemization and aiding the coupling of amino acids. In many labs, it rests next to carbodiimides—think DCC or EDC—since both together give better yields and cut down on unwanted reactions. In the industry, HOBT Pharma Grade—following BP, EP, USP monographs—often appears in the documentation supporting the manufacture of critical active ingredients and pharmaceutical intermediates.
Physically, HOBT Monohydrate displays the kind of stability chemists look for: melting points usually fall around 150-156°C, and the powder stays free-flowing under typical storage. The chemical structure—C6H5N3O•H2O—gives it a molecular weight near 171.15 g/mol. Hydrogen bonding with the water of crystallization adds another level of safety and workability, reducing some of the shock sensitivity risks faced with the anhydrous form. HOBT is only weakly acidic, showing pKa values near 5.2, which matters when selecting solvents. Low impurity levels set the Pharma Grade apart from industrial types. Solubility in DMF, DMSO, and methanol helps in various peptide and organic syntheses.
Manufacturers following BP, EP, or USP standards carefully document water content, purity (sometimes >99%), and heavy metal thresholds below tough international safety limits. Labels often show batch numbers, expiry dates, and recommended storage conditions—usually cool, dry, out of direct sunlight. There’s no room for shortcuts here; pharma companies expect detailed CoAs with HPLC or GC results proving identity and purity, plus loss on drying tests. Every lot must test negative for explosive tendencies under prescribed storage and shipping instructions. The proper packaging matters too; HOBT travels in sealed containers that block out light and moisture, answering the needs of regulatory inspectors and company quality managers alike.
On the manufacturing side, most companies start synthesis from o-nitroaniline to make benzotriazole, followed by hydroxylation, then controlled crystallization with water to lock in the monohydrate form. Controlling this last step handles both safety issues and downstream process efficiency. The industry keeps improving the preparation route. Greener solvent choices, in-process monitoring, and automated crystallizers make newer HOBT supply chains safer and more consistent. As chemical manufacturers face scrutiny over waste and emissions, HOBT production lines now favor recyclable solvents and better yield optimization.
HOBT most often shows its worth in coupling chemistry, especially peptide synthesis. When paired with carbodiimide reagents—like EDC or DCC—HOBT steps in to form the active O-acylisourea intermediate, and then smoothly leads to the amide bond with less chance of racemization. Beyond peptide bonds, some chemists use HOBT to activate carboxylic acids for making esters or amides of other types. Derivatives such as HOAt (7-aza analog) sometimes replace HOBT in tricky couplings, but HOBT remains cheaper and widely available for standard applications. Even with advances in click chemistry and new coupling strategies, HOBT continues to see routine use in day-to-day operations where reliability comes first.
Throughout the literature and supply catalogs, HOBT goes by several alternate names: 1-Hydroxybenzotriazole, 1-Hydroxy-1,2,3-benzotriazole, HOBt·H₂O, and sometimes 1H-Benzotriazol-1-ol monohydrate. Different manufacturers echo these names in UPC or regional distribution codes. Chemists might know both the anhydrous and monohydrate forms, but regulatory and supply chain documentation must always make the form explicit—important for shipping and for any risk management review of explosive potential.
Any lab worker with experience in organic synthesis will warn about safety. HOBT itself is less problematic than its dry anhydrous cousin, thanks to the monohydrate’s higher water content. The anhydrous version can be sensitive to friction, heat, and shock—raising real concern in storage and shipment. Standard protocols call for dust control, anti-static measures, and work in well-ventilated areas, especially on a large scale. Operators must rely on personal protective equipment, and any spillage must get quick cleanup with lots of water. Waste goes in separate, labeled organic bins, and manufacturing companies set up clear evacuation instructions for spill or fire situations. In regulated environments, authorities check SDS documents and demand proof of training for those handling any hazardous form of benzotriazole additives. Ongoing education in hazard handling and early reporting of symptoms ensures a better safety culture in pharmaceutical environments.
In practice, HOBT’s main job lands in pharmaceutical research and the production of peptide-based ingredients. Peptide drugs have seen a real surge due to their specificity and the rising number of diseases now addressed by peptides—think diabetes, cancer, or auto-immune therapies. Scale-up operations depend on HOBT’s predictability for attaching protected amino acids under GMP (Good Manufacturing Practices). Some CROs (contract research organizations) rely on HOBT for rapid prototyping of peptide segments during development. Specialty polymers and agrochemical intermediates also use HOBT in select coupling steps, though demand from the pharma industry shapes the bulk of the global market.
HOBT stands as a benchmark in coupling chemistry, but it still draws new research. The relentless quest to speed up peptide production drives scientists to test new solvents, catalytic systems, and automation-friendly protocols. Many academic papers compare HOBT’s efficiency against newer benzotriazole derivatives; some try to tweak molecular design to lower residual toxicity and enhance selectivity. R&D labs sometimes probe HOBT’s reactivity with non-natural amino acids or use it in solid-phase peptide synthesis (SPPS) workflows. Some institutions research on-site synthesis or stabilization methods to ship HOBT as a safer slurry, rather than as a dry solid, to address handling risks.
Plenty of work investigates the health and environmental risks tied to HOBT and its close relatives. While monohydrate form is less hazardous than the dry powder, accidental inhalation or ingestion draws attention from workplace safety teams and environmental regulators. Most handled exposures lead to irritation or mild systemic effects rather than acute toxicity, but repeat contact over months adds risk. Recent studies track benzotriazole compounds and their breakdown in soil or water waste; some findings raise mild concerns about persistence and bioaccumulation, pressuring manufacturers to deploy cleaner processing steps and effective waste treatment. Proper disposal and environmental monitoring remain a must for any firm operating in an area where HOBT use is high.
As peptide therapeutics keep rising and more research groups jump into the field, HOBT’s value doesn’t look set to fade. Some companies see opportunity in developing safer, more eco-friendly forms that keep all the chemical benefits while dialing down explosivity and toxicity. Regulatory requirements tighten every year, pushing producers to cut residual contaminants and adopt truly sustainable practices. Digital process control, single-use bioprocessing, and closed reactor technologies may make shipping and using HOBT much safer. Looking ahead, research collaborations between chemical manufacturers and universities could produce more stable derivatives, new coupling additives, or smarter handling protocols, ultimately benefiting pharma, biotech, and the producers who carve out a living in the specialty chemicals sector.
Pharmaceutical labs face a never-ending quest for reliable, efficient tools that cut down on byproducts, wasted resources, and delays. One standout helper in this arena: Hydroxybenzotriazole Monohydrate, better known as HOBT. Chemists everywhere keep this compound close at hand because it solves the messiest part of peptide synthesis. Peptide bonds require careful handling, or else substances clump together in unexpected ways, wasting precious raw materials and time.
Every researcher in a drug lab knows how sticky things can get during peptide coupling. Proteins and peptides make up the backbone of modern medication, from diabetes management to viral research breakthroughs. Making these chains requires tightly controlled chemical reactions. If the reaction runs too hot or too wild, unwanted byproducts can drag down yield and quality—add complications during purification, and the whole batch turns into a headache.
Hydroxybenzotriazole Monohydrate comes in as a solid, white powder you can easily weigh and dissolve. Its chemistry lets it catch stray chemical fragments that might otherwise trigger side reactions. HOBT helps direct the process toward the formation of strong, clean peptide bonds—essential for researchers trying to build complex molecules, like those used in anti-cancer therapies or advanced vaccine projects.
I remember working with a team set on designing a novel peptide-based antibiotic. Every trial without HOBT brought disappointment: yields hovered below forty percent, and cleaning up impurities ate into the clock. Once we started using HOBT, yields jumped higher, and the number of side-products shrank dramatically. That change did not just feel good on paper. It cut down the cost of raw materials and simplified approval steps for quality assurance. Other researchers echo this experience, especially those handling sensitive amino acids prone to forming unwanted linkages.
While effective and practical, HOBT comes with its own baggage. Concerns about handling safety entered the conversation in recent years. Some forms of HOBT dry out and turn shock-sensitive, which means storing and transporting it demands attention. Several pharmaceutical producers responded by switching to HOBT monohydrate, a more stable version compared to its anhydrous cousin. Keeping moisture in the structure seems to decrease risks of accidental ignition, and safer lab protocols help prevent avoidable incidents.
Green chemistry offers another pathway forward. Researchers now search for alternatives or modifications to HOBT, seeking agents that do the same job with less environmental impact and lower hazard potential. Until better replacements prove themselves, careful handling, rigorous safety checks, and regulatory guidance will shape HOBT’s use in the field.
Every chemical tool in drug manufacturing lands under regulatory scrutiny. The FDA and EMA expect clean, documented processes that minimize byproducts and support robust product quality. Because HOBT is so closely tied to these outcomes, pharmaceutical firms keep detailed logs about its sourcing, purity, and use. Standard operating procedures demand that everyone involved gets proper training, making safety and traceability key priorities.
Working with HOBT means blending chemical skill, practical experience, and a commitment to safety. As drug discovery advances, techniques and reagents will adapt, but the value of compounds like HOBT—those that boost results and cut down waste—remains clear to every lab bench chemist and regulatory official alike.
HOBT, or 1-Hydroxybenzotriazole, shows up in many lab settings, especially for peptide synthesis. Most chemists and pharma folks already know that not all batches are created equal, but the real question comes up: Should you grab the BP, EP, or USP grade? Sometimes, budgets steer choices, but patient safety and the success of a production run always depend on the details baked into these three little acronyms.
Three pharmacopeias—British (BP), European (EP), and United States (USP)—stand behind the quality and purity standards for HOBT. They write the rules, update them, and check on compliance. Each authority audits manufacturers and suppliers to make sure listed requirements line up with every batch sold under those letter grades. The labels look similar, but meeting one set of requirements rarely pleases all three.
Companies shipping HOBT under BP or EP have to deliver close to the monograph’s expectations for things like assay value and impurity fingerprints. For example, BP and EP often agree on allowable water content and ash residue, but they sometimes split on limits for certain heavy metals or specific related substances. USP usually asks for tighter microbiological checks, especially if drugs will touch the ingredient later in the process.
In my own experience as someone who has served both pharma research and production teams, a minor difference between residual solvents or endotoxin levels can mean the difference between signing off on a batch or discarding it entirely. I have seen cases where material taken from a BP supplier landed in a US lab, only to be requalified because the USP called for an unusually low particle count. That slowed everything down and cost more money, just because the initial specification did not align with local rules.
One overlooked angle involves paperwork. European and British pharmacopoeias put extra attention on full traceability and batch tracking. European regulations lean on detailed impurity profiles, while USP wants thorough documentation around storage and transport. Regulators don’t just trust test results; they want up-to-date records following every lot from raw material to shipment. That means companies using HOBT for anything close to a regulated drug might find themselves filling out an entirely different form set depending on the grade.
Labs chasing regulatory approval in Europe almost always ask their suppliers to provide materials with an EP monograph. US-based companies can run into surprise inspections that focus on USP compliance. Even a material that passes all analytical checks sometimes hits a snag if the paperwork doesn’t line up.
If you work in international supply or run a chemistry operation crossing borders, some hard choices come up. Running everything at USP grade can drive up cost, but skimping might mean delays or failed audits. For small manufacturers, that risk cuts into already slim margins.
Teams can start by reviewing which grade matches the final product’s destination and by talking directly with suppliers before buying large lots. Getting technical data sheets that list every critical impurity, handling step, and validated test makes those surprise checks much less risky. It pays off to keep records organized and train lab staff on the subtleties between BP, EP, and USP demands. Some companies partner with third-party labs capable of certifying compliance to more than one of the major pharmacopoeias, which eases global distribution headaches and gives regulators what they want right away.
Aligning documentation, testing protocols, and supplier agreements with the ultimate product market keeps operations running and avoids expensive hiccups. From what I’ve seen, putting in the legwork upfront almost always costs less than scrambling to requalify a batch mid-project—or watching a shipment sit on the dock because it missed a single line in the EP or USP documentation.
Working in the pharmaceutical field for years, I’ve seen how small oversights in chemical storage turn into big problems. Hydroxybenzotriazole Monohydrate, known for its role in peptide synthesis, does important work in the lab, but it comes with risk. Some stories come to mind from facilities where improper storage led to unexpected chemical reactions—events that served up lessons the hard way. Keeping this compound safe means treating it with respect and learning from the people who’ve handled it before.
Direct light, heat, and moisture threaten the stability of HOBT. Dry, cool spaces give the best security. Climate-controlled stockrooms keep fluctuations in check, with temperatures matching the recommendations from the manufacturer. Many facilities invest in well-sealed containers, using desiccant packs to draw away moisture. I’ve seen good results with amber glass bottles—these shield from light better than clear plastics ever could. Labeling stays clear, with bold dates and hazard warnings up front. Regular stock checks, with logs for batch numbers and expiration dates, leave little room for confusion and support traceability.
This compound plants itself on lists of materials with explosion and fire hazards. HOBT isn’t something you want sitting near flammable solvents, oxidizers, or parts of the lab where static electricity might spark danger. Storing small quantities, split between locations if possible, lowers the scale of any potential incident. I once visited a lab that put all explosive-prone chemicals in vented, locked cabinets—smart planning that paid off in safer day-to-day operations.
I always start preparation of HOBT solutions with full protective gear: lab coats, goggles, gloves, and a working fume hood. Skin and eyes need serious protection from contact. Even the dust deserves caution. Some operators use dust extractors or special vacuums to gather any loose powder. Training plays a big role—everyone on the team has to know the risks, the right response for spills, and the procedures for safe transfer between containers. Eye wash stations and emergency showers stand ready in many facilities. These rarely earn a second glance until the day they're needed, and then they mean everything.
Accidents still happen, even in labs with strict controls. Over my career, the fastest clean-ups followed clear plans and quick thinking. Small spills get covered right away with inert materials, collected in labeled, sealed waste containers. Larger spills prompt an evacuation and calls for the safety team. No shortcuts—local fire codes and environmental rules shape every disposal procedure. Regular drills keep people sharp and ready to act.
Safety grows from a shared attitude. Open communication about near-misses teaches much more than silent recovery ever could. Periodic reviews of safety procedures strengthen routines and catch problems before they escalate. New employees shadow veterans, picking up habits that make a difference. Investing in proper training and safety gear isn’t just a line-item expense; it pays off through fewer disruptions, healthier teams, and better outcomes in the lab.
Anyone who's ever worked in a lab, especially in peptide synthesis, knows HOBT isn't just another shelf chemical. It helps activate carboxyl groups, making peptide bonds happen more efficiently and with fewer by-products. The catch? A touch of impurity in your HOBT bottle can create bigger headaches downstream—everything from reduced yields to tricky purification steps. That's why manufacturers and users watch purity specs like hawks.
Pharmaceutical grade HOBT usually comes with a typical assay specification landing at no less than 99%. That’s not just a number on a certificate. It means for every hundred grams in your bottle, ninety-nine grams will actually do the job you bought it for. The rest—no more than that single gram—could be water or organic by-products left from production, but tight controls are in place to ensure none of those residuals spoil a multi-million-dollar synthesis batch.
Labs sticking to Good Manufacturing Practice (GMP) demand even tighter controls. I remember visiting a facility where a technician ran HPLC checks every day. Even a 98.5% batch raised eyebrows; in that environment, 99% wasn’t a boast, it was the minimum. Residual solvents, limit tests for heavy metals, and a strict moisture content cutoff (usually below 0.5%) are part of the full purity picture. If the certificate doesn’t mention heavy metals below 10 ppm or ensure no more than 1% water, most seasoned chemists keep shopping.
There’s a world of difference between "good enough" and "meets pharma grade." Using HOBT with unknown or low purity introduces risk. The impurities won’t always show themselves right away, but they can bind with APIs and form unpredictable by-products. One time, a lower-purity HOBT lot led to a field complaint after strange peaks popped up in QC chromatograms. Insurance companies love stories like that—production managers don't.
The FDA keeps a close eye on raw material quality for drug manufacturing. They have flagged issues with impurities in coupling reagents, including HOBT, in several warning letters. Skimping on specs invites audits and repeat testing, adding days and dollars to every release cycle. Data from the European Pharmacopoeia and USP support this focus: their monographs line up with the 99% purity mark and spell out the importance of keeping impurities (including water and residual organic solvents) below critical thresholds.
For a chemist or purchasing lead, spotting the right certificate of analysis is half the battle. Clear labeling, batch-to-batch consistency, and prompt technical support from the supplier are no less important than a precise assay number. One solution for tighter control is working with trusted vendors willing to provide batch history, validated test methods, and regular updates as standards evolve. If something looks off—a cloudy solution, a musty bottle, or inconsistent results—it pays to halt production and trace the issue before it spreads.
With increased demand for synthetic peptides and specialty drugs, the need for ultra-clean HOBT keeps going up. Suppliers who invest in in-house testing and transparent traceability often build stronger relationships with their pharma clients. From my experience, the cost saved by cutting corners gets lost in the next failed batch or recall. The real win? Tight specs and open communication between labs, suppliers, and regulators keep the science moving and the clinics safe.
HOBT—short for 1-Hydroxybenzotriazole—shows up a lot in labs, especially in peptide synthesis. From personal experience of working in a chemistry research setting, people often reach for HOBT like it’s any other lab supply. The truth is, risks with HOBT can sneak up if you aren’t paying close attention.
Some chemicals ask for more respect in the lab, and HOBT is one of those. Dry HOBT ranks high as a potential explosive hazard. I remember reading incident reports where small amounts, left to dry in a fume hood, went off with nothing but friction from a spatula. HOBT doesn’t need flames or spark; pressure and shock can do the trick. Its instability increases once dry, which catches even experienced chemists off guard. In my own lab, we always ordered it in the hydrate form, which cuts down risk by making it less sensitive. Many companies ship the monohydrate for this reason, choosing safety over convenience.
HOBT has a reputation in shipping departments. When moving chemicals around, forgetting what you packed can turn into a disaster. Years back, a colleague watched a package flagged at customs hold up an entire project because dry HOBT sent up red flags on documentation. International regulations (like UN0508) don’t give much wiggle room. HOBT can fall under “explosives” for shipping, so chemical supply companies add that wetting agent or hydrate before shipping anything out. I remember how much time it took to find compliant shipping partners. Anyone in logistics probably knows the feeling—that itch that something may get returned if every box hasn’t been ticked. Proper labeling, safety sheets, package cushioning, and declarations serve real purpose beyond red tape: they keep warehouse staff and transport workers safe without them even knowing it.
Leaving HOBT in the wrong place can spell trouble. I recall a situation where a new student stashed a barely used bottle next to acids. The potential for a dangerous reaction never crossed her mind. Moisture control, cool storage, and keeping it away from reactive agents count as basics. In a busy research space, one careless move multiplies risks. Safe storage isn’t glamorous, but avoiding surprises speaks for itself. I always check that bottles have clear hazard labels and aren’t overcrowded on the chemical shelf.
Solving the HOBT hazard puzzle doesn’t need a revolution. Insist on purchasing the monohydrate form. Review and refresh lab safety training, not just in theory but hands-on: show new staff what HOBT looks like, where it’s stored, who can use it, and how to handle spills. Make it standard to keep opened bottles sealed tightly, and enforce disposal policies for old stock. Spill kits, fire blankets, and proper PPE—lab coats, goggles, gloves—never just sit in the room for decoration. They make the difference. Sharing case studies or incident reports at lab meetings, as we often did, leaves an impression stronger than any warning sign on a bottle.
HOBT’s value in research can’t be denied, but treating it like any other solid ends in trouble. By setting thoughtful safety rules and treating every bottle as a potential hazard, labs and workers come home safe at the end of the day. It’s a lesson handed down and worth repeating—it only takes one oversight to remind everyone why these practices exist.
| Identifiers | |
| EC Number | 123333-53-9 |
Chengguan District, Lanzhou, Gansu, China
